Prescient Therapeutics (FRA:UDD) Inventory Turnover: 0.00 (As of Dec. 2025)


FRA:UDD Prescient Therapeutics Ltd FRA:UDD
22 GF Score
Price €0.03
! 2 Warning Signs
View Full Analysis

What is Prescient Therapeutics Inventory Turnover?

Prescient Therapeutics FRA:UDD +1.64% 22 Inventory Turnover is 0.00 as of Dec. 2025. GuruFocus rates FRA:UDD with a GF Score™ of 22/100. The stock has 2 warning signs investors should review.

Inventory Turnover measures how fast the company turns over its inventory within a year. It is calculated as Cost of Goods Sold divided by Total Inventories. Prescient Therapeutics's Cost of Goods Sold for the six months ended in Dec. 2025 was €0.00 Mil. Prescient Therapeutics's Average Total Inventories for the quarter that ended in Dec. 2025 was €0.00 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.


Prescient Therapeutics  (FRA:UDD) Inventory Turnover Explanation

Inventory Turnover measures how fast the company turns over its inventory within a year. A higher Inventory Turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Prescient Therapeutics's Days Inventory for the six months ended in Dec. 2025 is calculated as:

Days Inventory =Average Total Inventories (Q: Dec. 2025 )/Cost of Goods Sold (Q: Dec. 2025 )*Days in Period
=0/0*365 / 2
=

2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Prescient Therapeutics's Inventory to Revenue for the quarter that ended in Dec. 2025 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Dec. 2025 ) / Revenue (Q: Dec. 2025 )
=0 / 0
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate Inventory Turnover. An average inventory is a better indication.


Prescient Therapeutics Inventory Turnover Related Terms


Prescient Therapeutics Inventory Turnover Historical Data

* Premium members only.

The historical data trend for Prescient Therapeutics's Inventory Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Prescient Therapeutics Inventory Turnover Chart

Prescient Therapeutics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Inventory Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Prescient Therapeutics Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Inventory Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:UDD
22GF Score
Prescient Therapeutics Ltd FRA:UDD
Inventory Turnover is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Prescient Therapeutics Inventory Turnover Calculation

Prescient Therapeutics's Inventory Turnover for the fiscal year that ended in Jun. 2025 is calculated as

Inventory Turnover (A: Jun. 2025 )
=Cost of Goods Sold / Average Total Inventories
=Cost of Goods Sold (A: Jun. 2025 ) / ((Total Inventories (A: Jun. 2024 ) + Total Inventories (A: Jun. 2025 )) / count )
=0 / ((0 + 0) / 1 )
=0 / 0
=N/A

Prescient Therapeutics's Inventory Turnover for the quarter that ended in Dec. 2025 is calculated as

Inventory Turnover (Q: Dec. 2025 )
=Cost of Goods Sold / Average Total Inventories
=Cost of Goods Sold (Q: Dec. 2025 ) / ((Total Inventories (Q: Jun. 2025 ) + Total Inventories (Q: Dec. 2025 )) / count )
=0 / ((0 + 0) / 1 )
=0 / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Inventory Turnover →
What does a Inventory Turnover of 0.00 mean?
Prescient Therapeutics (FRA:UDD) has a Inventory Turnover of 0.00 as of Dec. 2025. Inventory turnover equals current-period cost of goods sold divided by average two-period total inventories. View historical data on Prescient Therapeutics and its competitors.
Is Prescient Therapeutics' Inventory Turnover too high?
Prescient Therapeutics' current Inventory Turnover is 0.00. Overall, Prescient Therapeutics has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Prescient Therapeutics' Inventory Turnover compare to VRTX and REGN?
Prescient Therapeutics' Inventory Turnover of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventory Turnover for a Biotechnology company?
A good Inventory Turnover depends on the Biotechnology industry context. However, Inventory Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventory Turnover mean?
A high Inventory Turnover can signal that a stock is expensive relative to its fundamentals. Inventory turnover equals current-period cost of goods sold divided by average two-period total inventories. View historical data on Prescient Therapeutics and its competitors. Prescient Therapeutics's current Inventory Turnover is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prescient Therapeutics stock overvalued right now?
Prescient Therapeutics (FRA:UDD) has a current Inventory Turnover of 0.00. The current Inventory Turnover is 0.00. Prescient Therapeutics' overall GF Score™ is 22/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventory Turnover calculated?
Inventory Turnover is calculated from a company's financial statements. For Prescient Therapeutics (FRA:UDD), the current Inventory Turnover is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Prescient Therapeutics Business Description

Other Exchanges PTX:Australia
Address 385 Bourke Street, Suite 2, Level 11, Melbourne, VIC, AUS, 3200
Prescient Therapeutics Ltd is a clinical-stage oncology company. The company develops novel compounds for the treatment of a range of cancers in Australia. Its product in the pipeline includes OmniCAR; PTX-100 and PTX-200. OmniCAR is a universal immune receptor platform enabling controllable T-cell activity and multi-antigen targeting with a single cell product.
22GF Score

Get the complete analysis for FRA:UDD

Inventory Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.03
Price